Viridian Therapeutics Stock Current Valuation
| 0K1R Stock | 15.30 0.05 0.33% |
Valuation analysis of Viridian Therapeutics helps investors to measure Viridian Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Viridian Therapeutics' Cash is comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 753.5 M in 2025, despite the fact that Free Cash Flow is likely to grow to (221.2 M). Fundamental drivers impacting Viridian Therapeutics' valuation include:
Enterprise Value 745.2 M | Price Sales 11.4966 |
Overvalued
Today
Please note that Viridian Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Viridian Therapeutics is based on 3 months time horizon. Increasing Viridian Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Viridian stock is determined by what a typical buyer is willing to pay for full or partial control of Viridian Therapeutics. Since Viridian Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viridian Stock. However, Viridian Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.3 | Real 13.93 | Hype 15.21 |
The intrinsic value of Viridian Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Viridian Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Viridian Therapeutics helps investors to forecast how Viridian stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viridian Therapeutics more accurately as focusing exclusively on Viridian Therapeutics' fundamentals will not take into account other important factors: Viridian Therapeutics Company Current Valuation Analysis
Viridian Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Viridian Therapeutics Current Valuation | 745.21 M |
Most of Viridian Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viridian Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Viridian Therapeutics has a Current Valuation of 745.21 M. This is 89.77% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The current valuation for all United Kingdom stocks is 95.52% higher than that of the company.
Viridian Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viridian Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viridian Therapeutics could also be used in its relative valuation, which is a method of valuing Viridian Therapeutics by comparing valuation metrics of similar companies.Viridian Therapeutics is currently under evaluation in current valuation category among its peers.
Viridian Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 745.21 M | ||||
| Shares Outstanding | 30.84 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 99.88 % | ||||
| Price To Sales | 11.50 X | ||||
| Revenue | 302 K | ||||
| Gross Profit | (237.95 M) | ||||
| EBITDA | (266.36 M) | ||||
| Net Income | (269.95 M) | ||||
| Total Debt | 21.09 M | ||||
| Book Value Per Share | 5.96 X | ||||
| Cash Flow From Operations | (232.32 M) | ||||
| Earnings Per Share | (5.14) X | ||||
| Number Of Employees | 143 | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 2.84 T | ||||
| Total Asset | 742.4 M | ||||
| Retained Earnings | (995.86 M) | ||||
| Net Asset | 742.4 M |
About Viridian Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viridian Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viridian Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viridian Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.